ARA-290 FAQ: common questions answered
Experimental peptide studied for small-fiber nerve damage, with uncertain pain relief and safety.
Also called: Cibinetide, ARA 290, ARA290, pHBSP, pHSBP, Pyroglutamate helix B surface peptide.
Healing and repair peptides · EPO-derived peptide designed to activate the innate repair receptor.
- Is ARA-290 FDA-approved? No approved product or label found in Drugs@FDA/openFDA searches. No cibinetide-specific PCAC decision or warning letter was located.
- How do people take it? Under the skin, once daily. 28 days. Source: studied in a trial.
- What's the difference between ARA-290 and BPC-157? ARA-290: experimental peptide studied for small-fiber nerve damage, with uncertain pain relief and safety. BPC-157: an experimental repair peptide with mostly animal evidence and a few small human reports. Why people pair them: people add it for tissue and nerve recovery.
- Can I take it with BPC-157? People add it for tissue and nerve recovery. Only three uncontrolled dental cases used a local multi-drug mixture. Routine combination safety is unproven. Source: reported by users. Ask a doctor before combining anything.
- Is it banned in sport? It is unclear (WADA 2026). The 2017 committee removed ARA290 from the innate repair receptor examples. No ARA290-specific ruling was verified for 2026; S0 applicability requires confirmation of current human therapeutic approvals worldwide.
- How long does a mixed vial last? No validated shelf life after community mixing was found. Refrigeration cannot establish potency or sterility.
Related to ARA-290
- BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.
- TB-500: A short piece of thymosin beta-4 with no proven repair benefit in humans.
- GHK-Cu: A copper-binding skin peptide with small topical studies and untested systemic injections.
- AHK-Cu: A copper peptide used in scalp serums, with laboratory findings and weak patent-only human data.
- Thymosin beta-4: A peptide studied for eye conditions and skin wounds; tendon-repair injections lack controlled human evidence.
- Ac-SDKP: An experimental repair peptide with old human studies, but no proven healing dose.
Sources
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding, FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Pyrogen and Endotoxins Testing: Questions and Answers, FDA · 2026
- Retraction Note: Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury., Patel NSA et al. · Molecular medicine (Cambridge, Mass.) · 2026
- Risks of buying peptide products online, Therapeutic Goods Administration · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Supply unlicensed medicinal products (specials), MHRA · 2025
- ERS clinical practice guidelines on treatment of sarcoidosis., Baughman RP et al. · The European respiratory journal · 2021
- Health, Medical & Research Committee (HMRC) Meeting Minutes, World Anti-Doping Agency · 2017
- EU/3/13/1191 - orphan designation for treatment of sarcoidosis, European Medicines Agency · 2013
- Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, FDA · FDA · 2000
- Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases., Froum S et al. · Frontiers in oral health · 2026
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.